Berberine

Based on the available evidence, berberine has been studied in multiple clinical trials, though comprehensive safety data remains limited. The compound has been investigated in completed and ongoing trials for various conditions including metabolic syndrome, prediabetes, and as an adjunct therapy.

Known Side Effects

Evidence is thin on systematic reporting of side effects. The provided studies focus primarily on efficacy outcomes rather than detailed adverse event profiles. One systematic review examined berberine as adjunctive therapy for schizophrenia with metabolic syndrome, but specific safety outcomes from this analysis are not detailed in the available evidence.

Contraindications and Populations to Avoid

Current evidence does not provide clear contraindications. However, the following considerations emerge from the clinical trial data:

• Pregnancy and breastfeeding: No safety data available for these populations
• Pediatric use: Available trials appear to focus on adult populations
• Severe hepatic or renal impairment: Safety in these populations has not been established

Drug Interactions

Limited evidence on drug interactions is available. One ongoing Phase 3 trial (NCT04860063) is specifically examining berberine's safety and efficacy in combination with antiretroviral therapy in people living with HIV, suggesting potential interactions with HIV medications are being investigated. However, results are not yet available.

The compound has been studied in combination with other natural products (resveratrol, 18-β-glycyrrhetinic acid) in topical formulations, but systemic interaction data is lacking.

Clinical Trial Safety Monitoring

Several completed and ongoing trials have incorporated safety evaluations:

• Multiple completed trials suggest berberine has been deemed safe enough for human studies
• An ongoing Phase 2/3 trial is examining sex-specific effects and safety
• One completed trial specifically evaluated safety in a lifestyle modification program

Evidence Limitations

The evidence base for berberine's safety profile is notably thin. While multiple trials have been completed or are ongoing, the provided abstracts do not contain detailed adverse event reporting or comprehensive safety analyses. More robust safety data from completed trials and systematic reviews would be needed to establish a complete safety profile.

This information is for educational purposes only and should not replace professional medical advice. Consult a healthcare provider before using berberine, especially if taking other medications or having underlying health conditions.